Objective:
To discuss the role of autologous serum tears (AST) in the treatment of dry eye disease (DED) and the significance of the shift in treatment paradigms towards personalized care.
Key Findings:
- AST showed greater improvement in OSDI and VAS scores compared to artificial tears in a randomized clinical trial involving 300 patients over 12 weeks.
- Safety outcomes for AST were favorable, with mild irritation reported in a minority of patients, indicating a good safety profile.
- The average patient cost for AST is about $130 per month, with some insurance coverage now available, which may improve accessibility.
Interpretation:
AST may provide significant benefits for patients with DED, particularly in cases requiring growth factor supplementation, and could become a first-line treatment option.
Limitations:
- AST has historically faced barriers related to preparation and accessibility, including variability in preparation conditions and lack of standardization.
- Further data on long-term efficacy and cost comparisons with other therapies is needed to fully understand its value.
Conclusion:
AST represents a promising treatment for DED, with potential for broader adoption as awareness and insurance coverage increase.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
